MAM
Munch Design forays into retail with Moh launch
BANGALORE: Munch Design Workshop Pvt. Ltd., a new age design BPO firm providing comprehensive design solutions to the apparel and related industries, has announced it is foraying into retail by launching Moh – a label of clothing and accessories.
Initially being retailed at Grasshopper, a fashion destination in Bangalore, the new label will provide a window to the innovation and design capability of Munch. The retail presence for the label would eventually expand in the domestic and international market.
The look of all the ranges in the new label would be earthy and classy with sophisticated quirks with the emphasis on comfort clothing, claims a release. Moh is a Hindi word and it means fondness.
Elaborating on the retail foray and the new Pr?t Label line, Karunesh Vohra, principal designer and CEO of Munch Design Workshop, said, “One of Munch’s key value propositions is trend forecasting where we identify and predict fashion and consumer trends for our clients. This places us in a unique vanguard position, from where we have the freedom to go in whichever direction we wish to and be different from the market. Compared to the existing market, Munch is unique as it is a design firm and not a studio or individual designer.”
“Munch is first of its kind outsourcing firm that plays in the niche space called design management services. Outsourcing of the kind that Munch is pioneering would see organizations effectively working with Munch as its extended design arm. This would be revolutionary as it would provide access to world class design talent, processes, and knowledge, which Munch has due to a large segment of clients, than say the leading one or two who have it in-house” added Vohra.
Charles Hayward II, Vice-president, Business Development of MFar Holdings who are the principal sponsors for the event where Munch will be showcased via the label said, “In recognition of our shared values and the desire to excel, we felt that Munch Design Workshop embodies the new breed of Indian entrepreneurship, that will propel India to the leading position as the service provider of the 21st Century. Our aim is to create partnerships with successful businesses that share the same vision.”
In its brief existence Munch claims to have established business relationship with clients like Westside, Precot Mills, Bangalore Central, Taj Hotel and Resorts, Tom Tailor, Levis- Dockers & Workers, Invista and Phillip Van Heusen among others. Munch is providing uniforms for the beach resorts of the Taj Group.
Their diverse portfolio may have different deliverables but the base is design. While Munch services Westside for most of their men’s wear brands, for Precot Mills (a leading textile manufacturer in Coimbatore) they are currently reengineering their corporate identity and packaging.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
